BIOMAT Database Logo BIOMAT Database Logo

[5-FU concentration in blood and tissue of patients with primary lung cancer after oral administration of UFT]. 1986

T Oiwa, and H Saito

Concentration of FT-207, 5-FU and Uracil in blood and normal lung tissue were estimated for lung cancer patients to whom UFT was orally administered. The histological types of these cases were as follows: 10 squamous cell carcinomas, 10 adenocarcinomas, 2 large cell carcinomas and 1 small cell carcinoma. Average concentration of 5-FU in these tumor tissues was 0.101 +/- 0.107 microgram/g. This was a significantly higher 5-FU concentration in comparison to those in serum and normal lung tissue. Comparison of 5-FU concentration between squamous cell carcinomas and adenocarcinomas showed no significant difference. Between metastasis-positive lymph nodes and metastasis-negative lymph nodes, there was also no significant difference in 5-FU concentration, but there was a significant difference in Uracil concentration. This result showed an effective transition of 5-FU from serum to tumor tissues with oral administration of UFT. It was therefore concluded that UFT would be expected to have an antitumor effect in primary lung cancer patients.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

T Oiwa, and H Saito
[Studies on 5-FU concentration in serum and prostate cancer tissue after oral administration of UFT].
July 1991, Hinyokika kiyo. Acta urologica Japonica,
T Oiwa, and H Saito
[5-FU concentration in blood and tissue of patients with renal cell carcinoma after administration of UFT].
February 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
T Oiwa, and H Saito
[5-FU concentration in tumor tissue and the antitumor effect in patients with gastric cancer after oral administration of UFT].
September 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
T Oiwa, and H Saito
[5-FU concentration in the blood and tissue of patients with gastric and colorectal cancer after administration of UFT or tegafur].
August 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
T Oiwa, and H Saito
[Studies on 5-FU concentration in serum and bladder tumor tissue after oral administration of UFT].
October 1986, Hinyokika kiyo. Acta urologica Japonica,
T Oiwa, and H Saito
[Level of 5-FU in uterine cervical cancer tissue after oral administration of UFT].
November 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
T Oiwa, and H Saito
[UFT in the treatment of primary lung cancer--5-FU concentration in the tissue and side effects].
June 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
T Oiwa, and H Saito
[5-Fluorouracil (5-FU) concentration in prostatic tissue of rats and in prostatic cancer patients after oral administration of 5-FU].
May 1990, Hinyokika kiyo. Acta urologica Japonica,
T Oiwa, and H Saito
[Concentration of 5-FU level in the tissue and blood of the patients with breast cancer by preoperative administration of UFT].
April 1982, Gan to kagaku ryoho. Cancer & chemotherapy,
T Oiwa, and H Saito
[Concentration of 5-FU and tegafur in the ascites fluid in patients with peritonitis carcinomatosa after UFT oral administration].
March 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!